Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension
- Authors: Moisseeva OM1, Rudakova AV2
-
Affiliations:
- СЗФМИЦ им. В.А. Алмазова Минздрава России, НИО некоронарогенных заболеваний сердца
- СПХФА Минздрава России
- Issue: Vol 89, No 3 (2017)
- Pages: 72-77
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32213
- DOI: https://doi.org/10.17116/terarkh201789372-77
- ID: 32213
Cite item
Full Text
Abstract
Aim. To provide a pharmacoeconomic estimate of macitentan versus bosentan in therapy for pulmonary arterial hypertension (PAH). Subject and methods. An analysis was carried out on the basis of a social perspective for patients, whose mean age was 50 years. A budget impact analysis was performed without discounting; with the time horizon of the study being 5 years. Assessing the cost- effectiveness of endothelin receptor antagonists used a Markov model based on the meta-analysis of clinical trials. The cost of bosentan was calculated from the 2016 registered prices with VAT. That of macitentan was estimated from the expected price of 170,000 rubles per 10-mg dose pack №28 if the drug is included in the List of Essential Medicines with VAT. The cost of sildenafil and iloprost was consistent with the January-to-November 2016 auction results. At cost-effectiveness assessment costs and outcomes were both discounted at an annual rate of 3,5%. Results. After 5 years of therapy with macitentan in patients with baseline Functional Class (FC) II PAH, the proportion of patients with FC I-II was shown to be 2.6% more than that during therapy with bosentan (20.1 and 17.5%, respectively), and that of the died patients was 1.5% lower (69.5 and 71%, respectively). In baseline FC III PAH following 5 years, the proportion of patients with FC III PAH on initial macitentan treatment was 1% more than that on bosentan therapy (8.1 and 7.1%, respectively), and that of the died patients was 0.5% lower (87.2, and 87.7%, respectively). The cost-effectiveness analysis shows that therapy with macitentan versus bosentan not only causes some increase in life expectancy in terms of quality of life (by 0.414 and 0.230 QALYs in FC II and III PAH, respectively), but also results in a small cost decrease in FC II and III PAH (by 11,000 and 16,000 rubles per patient, respectively). Thus, macitentan is a dominant alternative versus bosentan. The budget impact analysis indicates that when bosentan is replaced with macitentan, the reduction in health care costs in the Russian Federation will amount to 1.9 million rubles over 5 years, and in all budgetary costs will be 14.7 million rubles. Conclusion. Treatment with macitentan in patients with FC II-III PAH is more cost-effective than that with bosentan and does not require an increase in budget costs.
Full Text
##article.viewOnOriginalSite##About the authors
O M Moisseeva
СЗФМИЦ им. В.А. Алмазова Минздрава России, НИО некоронарогенных заболеваний сердцаСанкт-Петербург, Россия
A V Rudakova
СПХФА Минздрава РоссииСанкт-Петербург, Россия
References
- Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barberà J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol Ç, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Völler H, Luis Zamorano J. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi: 10.1093/eurheartj/ehv317
- Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016;68(2):357-418. doi: 10.1124/pr.115.011833
- Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis. 2014;8(5):202-216. doi: 10.1177/1753944714541511
- Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G;SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818. doi: 10.1056/NEJMoa1213917
- Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension N Engl J Med. 2002;346(12):896-903. doi: 10.1056/NEJMoa012212
- Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome:a multicenter, double-blind, randomized, placebo-controlled study Circulation. 2006;114(1):48-54. doi: 10.1161/CIRCULATIONAHA.106.630715
- Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123. doi: 10.1016/S0140-6736(01)06250-X
- Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N, STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049-2056. doi: 10.1016/j.jacc.2006.01.057
- Galie N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100. doi: 10.1016/s0140-6736(08)60919-8
- Tran K, Coyle K, Jabr MF, Coyle D, Boucher M, Mielniczuk L, Swiston JR, Rabb D, Cimon K, Blouin J, Innes M. Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness Report of Canadian Agency for Drugs and Technologies in Health. 2015:337. Available at: 18.01.2017. The link is active on: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0086667/
- Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin L, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. Chest. 2017;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473
- Мешков Д.О., Хабриев Р.У., Безмельницына Л.Ю., Лоскутова О.Ю., Берсенева Е.А., Черкасов С.Н. Клинико-экономический анализ эффективности применения препарата Мацитентан (ОПСАМИТ) при легочной артериальной гипертензии в условиях Российской Федерации. Бюллетень Национального научно-исследовательского института общественного здоровья им. Н.А. Семашко. 2015;Вып.6:121-140.
![](/img/style/loading.gif)